Press

Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers

Jan 31 • 2 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that its wholly-owned subsidiary Psilo Scientific Ltd. has been included in Health Canada’s list of licensed psilocybin producers. This list is available upon request to parties interested in access to psilocybin through the Special Access Program (SAP) or…

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Jan 29 • 4 min read

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today launched Invyxis, a new, wholly owned platform company committed to developing new chemical entities (NCEs) and to further pioneering next-generation mental health treatments. Invyxis will bring proven medicinal chemistry tools and comprehensive biological screening…

Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions

Jan 29 • 2 min read

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announces the filing of a patent application for a new chemical series of entactogen-like molecules, further strengthening Awakn’s intellectual property portfolio and pipeline for the treatment of a broad range of addictions…

Mindset Pharma Enters Manufacturing Agreement to Produce Next-Generation Psilocybin Drug Candidate, MSP-1014

Jan 25 • 2 min read

Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has entered into a pharmaceutical manufacturing agreement with a leading contract development and manufacturing organization, for the production of pharmaceutical grade batches…

G2 Acquires Lophos Pharma, a peyote focused psychedelics company

Jan 24 • 2 min read

Greenridez 2.0 Acquisitions Corp. is pleased to announce that it has completed its acquisition of psychedelic research company Lophos Pharma. Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). The Company strongly supports Lophos Pharma’s belief in Peyote’s potential to treat indications ranging from weight loss…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441